Background-The transcription factor hepatocyte nuclear factor (HNF)-1␣ regulates the activity of a number of genes involved in innate immunity, blood coagulation, lipid and glucose transport and metabolism, and cellular detoxification. Common polymorphisms of the HNF-1␣ gene (HNF1A) were recently associated with plasma C-reactive protein and ␥-glutamyl transferase concentration in middle-aged to older European Americans (EA). Methods and Results-We assessed whether common variants of HNF1A are associated with C-reactive protein, ␥-glutamyl transferase, and other atherosclerotic and metabolic risk factors, in the large, population-based Coronary Artery Risk Development in Young Adults Study of healthy young EA (nϭ2154) and African American (AA; nϭ2083) adults. The minor alleles of Ile27Leu (rs1169288) and Ser486Asn (rs2464196) were associated with 0.10 to 0.15 standard deviation units lower C-reactive protein and ␥-glutamyl transferase levels in EA. The same HNF1A coding variants were associated with higher low-density lipoprotein cholesterol, apolipoprotein B, creatinine, and fibrinogen in EA. We replicated the associations between HNF1A coding variants and C-reactive protein, fibrinogen, low-density lipoprotein cholesterol, and renal function in a second population-based sample of EA adults 65 years and older from the Cardiovascular Health Study. The HNF1A Ser486Asn and/or Ile27Leu variants were also associated with increased risk of subclinical coronary atherosclerosis in Coronary Artery Risk Development in Young Adults and with incident coronary heart disease in Cardiovascular Health Study. The Ile27Leu and Ser486Asn variants were 3-fold less common in AA than in EA. There was little evidence of association between HNF1A genotype and atherosclerosis-related phenotypes in AA. Conclusions-Common polymorphisms of HNF1A seem to influence multiple phenotypes related to cardiovascular risk in the general population of younger and older EA adults. (Circ Cardiovasc Genet. 2009;2:244-254.)
types. Rare, heterozygous mutations of HNF1A are responsible for the autosomal dominant disorder mature-onset diabetes of the young type 3. 9 In several recent genome-wide analyses, common variants of the HNF1A region on chromosome 12 were associated with circulating levels of fibrinogen, 10 C-reactive protein (CRP), 11, 12 and ␥-glutamyl transferase (GGT). 13 Whether HNF1A variants are associated with these or other atherosclerotic and metabolic phenotypes in independent community-based samples that include nonwhite populations is unknown.
Inflammation and thrombosis biomarkers, such as CRP and fibrinogen, are correlated with one another and tend to cluster with other atherosclerotic and metabolic risk factors, such as cholesterol, insulin resistance, as well as with markers of oxidative stress, such as GGT. 14, 15 Genetic coregulation by transcription factors, such as HNF-1␣, might explain some of the correlation between atherosclerotic phenotypes. In addition, variants of genes that pleiotropically influence several etiologic pathways may be good candidates for association with complex, multifactorial vascular phenotypes, such as coronary atherosclerosis. This is an important goal clinically because identification of genetic markers that predict coronary disease may ultimately allow targeting of susceptible individuals for aggressive risk modification or drug therapy. Therefore, we assessed whether common variants of HNF1A are associated with various atherosclerotic and metabolic risk factors, as well as the more complex phenotype of subclinical coronary atherosclerosis, in a large, population-based study of apparently healthy young European American (EA) and African American (AA) adults. To further assess the clinical relevance of HNF1A polymorphisms, we replicated our association findings with multiple CVD-related phenotypes in a US population-based sample of older adults who are at higher global risk for developing clinical coronary heart disease.
Methods

Coronary Artery Risk Development in Young Adults (CARDIA) Study Participants and Phenotype Measurements
The CARDIA Study is a prospective cohort study of the development of cardiovascular risk factors in young adults. 16 In 1985 to 1986, 5115 participants aged 18 to 30 years were recruited from 4 clinical sites located in Birmingham, Ala; Chicago, Ill; Minneapolis, Minn; and Oakland, Calif. CARDIA Study subjects were recruited to be balanced on age, sex, ethnicity, and educational attainment. Participants were reexamined at 6 follow-up examinations with overall retention rates among surviving participants of 91% at year 2, 86% at year 5, 81% at year 7, 79% at year 10, and 74% at year 15, and 72% at year 20. Those eligible for the current study were 4304 consenting participants who had DNA aliquots available for genotyping.
Measurement of the plasma CVD biomarkers CRP, fibrinogen, cholesterol, apolipoprotein B, GGT, aspartate aminotransferase, creatinine, glucose, and insulin were performed at various CARDIA examination time points, as described under supplemental methods. Coronary artery calcium (CAC), a measure of subclinical coronary atherosclerosis, was determined at the year 20 CARDIA examination by electron beam or multidetector computerized tomography scanning using methods that have been previously described. 17 For each CVD biomarker, multiple measurements were available for most participants, but each biomarker was measured at different time points (supplemental Table I ). Therefore, for each biomarker, covariate-adjusted (age, sex, BMI, and smoking) Z-score values derived at each time point were averaged to obtain a composite standardized value for each participant (see supplemental methods for further details). This final averaged value was used as the phenotype (dependent variable) in regression models assessing association with HNF1A genotype. The approach of averaging multiple phenotypic measures over time can help to reduce the effects of measurement error and environmental variation, thereby providing a more stable estimate of the phenotype and enhancing power to detect true genetic signals. 11
HNF1A SNP Selection and Genotyping
Six SNPs in HNF1A (rs1169288, rs2071190, rs2259820, rs2464196, rs3999413, and rs1882149) were typed in 4304 CARDIA participants (2129 AA and 2175 EA). The rs1169288, rs2259820, and rs2464196 polymorphisms were selected because they encode previously known nonsynonymous HNF1A exonic substitutions that alter the coding sequence. The remaining 3 tag SNPs were selected on the basis of having a minor allele frequency of Ͼ10% in EA and providing nonredundant coverage of linkage disequilibrium (LD) patterns across HNF1A. It should be noted that these SNPs were selected using sequence variation data from the Perlegen database in 2003, before the availability of more comprehensive sequence variation databases such as the current version of the HapMap. When assessed against the current release of the HapMap, using an allele frequency threshold of Ͼ5% and a multimarker LD tagging strategy of r 2 Ͼ0.7, 18 the selected HNF1A SNPs tag 6 of 12 common LD bins (50%) present in Europeans and 4 of 14 LD bins (29%) in Africans.
Polymorphisms were genotyped using the TaqMan assay (Applied Biosystems, Foster City, Calif) as previously described. 19 Primer and probes are available from the authors on request. Polymorphism genotyping in the CARDIA Study adheres to a rigorous quality control program, which includes barcode identification of samples, robotic sample handling, and blind replicate genotype assessment on 5% of the total sample.
After excluding 67 participants with missing genotype data at 2 or more SNPs, the total missing genotype rate was 1.5% and ranged from 0.5% to 2.6% per SNP. Genotypes at rs2259820 and rs2464196 were highly correlated (pair-wise r 2 ϭ0.997 in EA and 0.962 in AA); therefore, rs2259820 was excluded from further analysis. The minor allele frequency of rs3999413 was Ͻ5% in AA, and therefore was excluded from analysis among the AA cohort.
Validation Cohort (the Cardiovascular Health Study)
The Cardiovascular Health Study (CHS) is a prospective populationbased cohort study of 5888 men and women aged 65 and older recruited from 4 US field centers: Forsyth County, NC; Sacramento County, Calif; Washington County, Md; and Pittsburgh, Pa. 20 The original CHS cohort (nϭ5201) was recruited from 1989 to 1990 and included 4925 self-identified EA and 246 AA. A second AA cohort (nϭ687) was recruited between 1992 and 1993. At study entry, CHS participants underwent assessment of CVD risk factors and fasting blood collection. 21 Blood CVD biomarker measurements from the baseline examination (year 0 for the original cohort or year 3 for the minority cohort) were performed at the Central CHS Laboratory at the University of Vermont, as described under supplemental methods. In addition to serum creatinine, cystatin C concentration was available as an alternative measure of renal function. The final CHS sample for the current study was restricted to 4352 EA and 790 AA men and women who consented to DNA testing. Several HNF1A tagSNPs, including the 2 noncoding variants rs1169288 and rs2464196, were typed in CHS as previously described. 11 Details of clinical CHD events ascertainment during CHS follow-up have been published. 22 Clinical CHD events were adjudicated by physician review panel according to medical records, death certificates, and supplemented by Medicare utilization data. Adjudicated events occurring through June 30, 2005 were available, which allowed for a maximum of 16 years of follow-up. For purposes of the current study, we analyzed all incident coronary heart disease events (angina, myocardial infarction, fatal CHD, coronary revascularization, or coronary bypass surgery) as a composite clinical CHD end point. Subjects with a history of CHD before baseline (847 EA and 152 AA) were excluded from the analysis of incident CHD events.
Statistical Analysis
Consistency of observed genotype frequencies with Hardy-Weinberg equilibrium within each self-reported race/ethnicity group was assessed by performing Pearson's 2 test. LD as a measure of allelic correlation between pairs of polymorphic sites was calculated as r 2 . Pair-wise LD calculations and haplotype estimation was performed using Haploview program version 4.1 (http://www.broad.mit.edu/ mpg/haploview/download.php).
Associations between individual SNP genotypes and biomarker phenotypes were assessed using linear regression, and adjusted for age, sex, BMI, and smoking. We assessed the association of HNF1A SNPs with subclinical coronary atherosclerotic disease defined as the presence of CAC at the year 20 CARDIA examination using logistic regression, initially adjusted for age, sex, and clinic. In CHS, associations with time to clinical CHD event were assessed using Cox proportional hazards regression and adjusted for age, sex, and major risk factors (smoking, diabetes, hypertension, low-density lipoprotein [LDL] cholesterol, BMI, and CRP) at baseline. All regression analyses were performed using the statistical package Stata/SE8.2 (Stata Corp, College Station, Tex). For our primary analysis, we assessed phenotypic associations with HNF1A SNP genotypes using an additive genetic model, assuming a constant, linear effect size for each additional copy of the minor allele. Covariate-adjusted SNP-specific change in estimated mean plasma biomarker level, odds ratio of CAC, or relative risk of CHD was estimated from the regression coefficients (␤). To assess whether a particular HNF1A genotype-CVD phenotype association was influenced by the presence of other risk factors, we repeated each analyses adjusting for additional CVD biomarkers, atherosclerotic, and metabolic risk factors. To combine HNF1A genotype-CVD biomarker phenotype association results across CARDIA and CHS, we used a variance-weighted meta-analysis approach that allows for heterogeneity of results between studies. 23 Procedures for adjustment of population stratification, correction for multiple hypothesis testing, and haplotype association analysis are described under supplemental methods.
Results
CARDIA Study Participant Characteristics, Phenotype, and Genotype Distributions
Descriptive characteristics of eligible CARDIA participants at the baseline (nϭ4304) and year 20 follow-up (nϭ3504) examinations are shown in Table 1 . The mean age at study entry was 25 years, and 55% were women. Current smoking, BMI, GGT, blood pressure, CRP, fibrinogen, and insulin resistance were higher among AA than EA. CAC scores at year 20 ranged between 0 and 6058, but the distribution was (6) 162 (10) 625 (14) 196 (25) C Data are presented as n (%) or meanϮstandard deviation, unless otherwise indicated. ND indicates not determined; HDL, high-density lipoprotein. *Fibrinogen was measured in CARDIA using an immunologic method (nephelometric assay); while fibrinogen was measured in CHS using a clotting rate method (modified Clauss assay).
†Coronary heart disease (CHD) defined as history of angina, myocardial infarction, or coronary revascularization.
highly skewed, with a mean score of 24. The prevalence of CAC (scoreϾ0) was higher among EA (21%) than AA (16% Table 2 , by race. The minor alleles of rs1169288 and rs2464196 were nearly 3 times as common among EA compared with AA. Within each race/ethnicity, each SNP was in Hardy-Weinberg equilibrium, except for rs2464196 in EA (Pϭ0.005). In pair-wise LD analysis (supplemental Figure  I) (Table 3 ). There was a nonsignificant trend toward lower log(CRP) and GGT among AA. At a nominal ␣ level of 0.05, the HNF1A rs1169288 or rs2464196 coding variant alleles were also associated with higher levels of total and LDL cholesterol, apolipoprotein B, and creatinine in EA, and with higher fasting glucose in AA. Except for the log(CRP), GGT, and creatinine phenotype associations in EA, the P values became nonsignificant (Ͻ0.05) after correction for multiple testing. There was no association between HNF1A genotype and fibrinogen, high-density lipoprotein cholesterol, insulin, or aspartate aminotransferase levels in models adjusted for age, sex, clinic, BMI, and smoking. When these analyses were additionally adjusted for other risk factors including CRP, the minor alleles of rs1169288 (␤ϭ0.11Ϯ0.03; Pϭ0.0002) and rs2464196 (␤ϭ0.13Ϯ0.03; Pϭ1ϫ10 Ϫ5 ) became strongly associated with higher fibrinogen levels in EA.
Haplotype analyses for selected phenotypes are shown in supplemental Table II Table II ).
Replication of HNF1A Genotype-CVD Biomarker Associations in CHS
The CHS participant characteristics are shown in Table 1 , stratified by race. The mean age was 73 years, 60% were female, and 15% were AA. Compared with CARDIA participants, CHS participants were older and at greater cardiovascular risk (19% had prevalent CHD at baseline). As shown in Table 4 , when the results for the most recent CARDIA examination (year 20; mean age 45) were compared with the results from the CHS baseline examination (mean age 73), the effect sizes and magnitude of the HNF1A genotypebiomarker associations were similar in EA for rs1169288 and rs2464196. The association between rs1169288, rs2464196 and CRP has been previously reported in CHS EA. 11 Here, we confirm that the variant alleles of HNF1A rs1169288 and rs2464196 coding SNPs are associated with higher total and LDL cholesterol and decreased renal function (as assessed by higher plasma cystatin C levels) in older EA adults from CHS. We also replicated the fibrinogen association, which again was only demonstrable on adjustment for CRP. Among 790 AA participants from CHS, there were no significant associations with HNF1A genotype, except rs1169288 was associated with decreased renal function, as indicated by increased serum creatinine and cystatin C levels (supplemental Table III ). In a pooled stratified analysis of 2873 AA subjects across CARDIA and CHS, none of the CVD biomarker phenotype associations was statistically significant (pooled PϽ0.05). (Table 5 ). In contrast, there was little evidence of association between HNF1A genotype and risk of coronary atherosclerosis in CARDIA AA. Conditional haplotype analysis in EA confirmed an independent association between CAC and rs2464196 (Pϭ0.02) but not rs1169288 (Pϭ0.12). Additional multivariable adjustment for other atherosclerotic risk factors ascertained at the year 20 examination (smoking, BMI, diabetes, hypertension, lipids, CRP, and fibrinogen levels) did not alter the rs2464196-CAC association (odds ratioϭ1.27; 95% CI, 1.04 to 1.56). When CAC score was analyzed as a quantitative variable, the age-, sex-, and clinic-adjusted P values were 0.08 for rs1169288 and 0.009 for rs2464196 in EA and 0.76 and 0.51 in AA. When the CAC association results for the rs2464196 Ser486Asn polymorphism were stratified by sex, there were no appreciable differences between men and women. In CHS, there were 1492 incident CHD events (myocardial infarction, angina, coronary bypass surgery or revascularization) during a median follow-up of 11.4 years. When adjusted for age, sex, race, smoking, BMI, diabetes, hypertension, lipids, CRP, and fibrinogen levels, the hazard ratio for CHD events associated with each additional copy of the minor allele of rs1169288 and rs2464196 were 1.12 (95% CI, 1.03 to 1.22; Pϭ0.008) and 1.10 (95% CI, 1.01 to 1.20; Pϭ0.026), respectively.
Discussion
Our findings from the population-based CARDIA cohort confirm results from recent genome-wide association studies [11] [12] [13] that common coding sequence variants of the transcription factor gene HNF1A (rs1169288 [Ile27Leu] and rs2464196 [Ser486Asn]) are associated with lower plasma CRP and GGT levels in EA adults. These HNF1A coding Associations are shown for individual SNP genotypes regressed on age-, sex-, BMI-, and smoking-adjusted Z-score values averaged across all CARDIA examination time points available for each biomarker, assuming an additive genetic model with constant effect size for each additional copy of the minor allele. ␤ Coefficients, SEs, and nominal P values correspond to the covariate-adjusted SNP-specific change in estimated mean plasma biomarker level in SD units. Adjusted P values are shown corrected for performing multiple hypothesis testing. NS indicates not significant (PϽ0.05); HDL, high-density lipoprotein.
*Adjusted for multiple testing (as described under Supplement Methods). †On additional adjustment for log(CRP), the associations, rs1169288 and rs2464196, and fibrinogen became statistically significant (see Results section).
variants also showed evidence of association with several other blood biomarker phenotypes related to CVD risk, including higher LDL cholesterol, apolipoprotein B, and fibrinogen levels and reduced renal function, in younger EA adults from CARDIA and older EA adults from CHS. Finally, there was some evidence that the HNF1A rs2464196 coding variant was associated with increased risk of subclinical coronary atherosclerosis and with incident clinical CHD. While this manuscript was under review, 2 large-scale genome-wide association studies (involving tens of thousands of subjects) were published mapping common HNF1A-risk alleles to higher plasma LDL levels 24 and increased risk of CHD 25 in EA, providing further validation for the association between HNF1A genotype and atherosclerosis outcomes. Together with the known role of HNF1A mutations in familial monogenic diabetes (mature-onset diabetes of the young), 9 the pleiotropic effects of HNF1A variants on multiple CVD and metabolic phenotypes highlight the role of HNF-1␣ as both a positive and negative transcriptional regulator of a large network of hepatic, renal, and pancreatic genes involved in inflammation, blood coagulation, insulin secretion, cholesterol synthesis, lipid transport, cellular detoxification, and renal function, 1-8 which in concert may act to influence overall susceptibility to coronary atherosclerotic disease.
The lack of statistically significant associations with lower CRP or GGT in AA might reflect reduced statistical power due to the 3-fold lower frequency of Ile27Leu and Se486Asn allele in AA compared with EA. Nonetheless, we were still unable to observe significant observations by performing a combined analysis of AA participants (nϭ2873) from CARDIA and CHS. Therefore, possible reasons for the lack of observed associations in AA include differences in genetic or environmental background or differential LD between SNPs in EA versus AA populations due to greater nucleotide diversity among Africans. It is becoming increasingly apparent that genetic differences exist between the determinants of CVD phenotypes in AA and EA. 26, 27 Moreover, it is important to note that SNPs typed in the current study covered only a fraction of the known genetic diversity of the HNF1A locus in Africans.
Although rare, heterozygous mutations in HNF1A are responsible for familial monogenic forms of diabetes (mature-onset diabetes of the young type 3), the role of common HNF1A polymorphisms in type 2 diabetes in the general population is less clear. The region harboring HNF1A on chromosome 12q24 has shown genetic linkage to diabetes in EA pedigrees, 28 but European and North American casecontrol studies of common HNF1A variants in type 2 diabetes have yielded conflicting results. 29 -31 Recently, the Ile27Val variant was associated with increased risk of type 2 diabetes in a population-based cohort study from Scandinavia. 32 These data again suggest the possible importance of genetic or environmental background on the association between common HNF1A polymorphisms and CVD-and metabolismrelated traits in the general population. HNF-1␣ has a complex role in coordinating hepatocytespecific gene expression. Promoter or enhancer HNF-1␣ binding sites are present in the structural genes encoding hepatic synthesis of many plasma proteins, such as CRP, 33, 34 fibrinogen, 35, 36 and apolipoprotein B. 37 In addition to positively regulating a large number of downstream target genes, HNF-1␣ can also modulate transcription indirectly by HNF-1␣-mediated negative regulation of genes activated by HNF-4␣. 38, 39 CRP and fibrinogen are both acute phase reactants that tend to be positively correlated, but they are not regulated in an identical manner. 40, 41 CRP is unique among acute phase reactants in which estrogen seems to have a major first-pass liver effect and up-regulates CRP while down regulating other acute phase reactants such as fibrinogen. 42 Together these observations support the complex genetic regulatory relationships that likely underlie the direction of some of the observed HNF1A genotype-CVD phenotypic associations, as well as the observation that by adjusting our fibrinogen analysis for CRP, we were able to uncover an HNF1A genotype-fibrinogen relationship that was distinct from the observed effect of HNF1A genotype on CRP. Although multiple phenotypic associations may suggest a common genetic cause (pleiotropy), it is also important to point out that such a scenario may also represent indirect genetic effects primarily with a subset of these phenotypes and/or complex nongenetic/environmental correlations between CVD traits. 43 Ultimately, the application of more complex multivariate statistical methods along with molecular functional studies will be required distinguish among these possibilities.
The association between the HNF1A Ser486Asn variant and increased risk of coronary atherosclerosis and CHD, despite the strong association of the Ser486Asn and Ile27Val alleles with lower levels of CRP and GGT, may have several possible explanations. Given the central but complex role of HNF-1␣ in transcriptional regulation, it is likely that the same HNF1A polymorphisms, besides their influence on higher LDL cholesterol and fibrinogen, affect the activity or expression of additional (unmeasured) phenotypes that influence initiation or progression of atherosclerosis. Supporting this possibility, the HNF1A genotype-CHD associations in CARDIA and CHS persisted despite adjustment for other traditional CVD risk factors, such as blood pressure, BMI, lipids, and other CVD biomarkers. Moreover, the HNF1A rs2259816 variant (which in strong LD with our rs2464196 typed SNP) associated with increased CHD risk in a recent genome-wide association studies showed no significant associations with other traditional CVD risk factors. 25 HNF1A variants may influence multiple atherosclerosisrelated genes or their plasma products through distinct effects on HNF-1␣ structure or function (ie, allelic heterogeneity). Ile27Leu and Ser486Asn are in LD with one another as well as with a number of other SNPs across the Ϸ24-kb HNF1A region on chromosome 12q24. 11, 12 For some phenotypes (CRP, lipids), the evidence has been stronger for association with rs1169288 (Ile27Leu), whereas for other phenotypes (GGT, creatinine, fibrinogen, CAC), the association appeared stronger for rs2464196 (Ser486Asn). Ile27Leu is located within the HNF-1␣ dimerization domain and has been associated with decreased in vitro transcriptional activity of downstream target gene promoters. 44 The Ser486Asn variant is located in the C-terminal transactivation domain of HNF-1␣ in a specific region implicated in target-gene specific recruitment and interactions with transcriptional coactivators. 45 By assessing typed SNPs and also imputing genotypes at untyped HNF1A polymorphisms from the HapMap, a cluster of 7 variants (rs7979473, rs7979478, rs2393791, rs2393775, rs7310409, rs10774579, and rs7953249) within a putative regulatory region of intron 1 showed the strongest evidence of association with CRP phenotype. 11 Differential splicing represents another potential level of functional influence of common HNF1A sequence variants. 46, 47 For example, rs2464196, rs2259820, and rs2464195 are all predicted to alter exonic splice enhancer elements. 48 In summary, common variants of HNF1A are associated with CRP and other atherosclerosis-related traits in EA adults. There are multiple mechanisms by which common HNF1A variants may alter gene and protein function. The identity of the functional variants responsible for the observed phenotypic associations remains to be determined through additional molecular studies. Finally, our findings suggest that assessment of genetic variants within additional genes encoding transcription factors involved in the complex regulatory network that govern liver-specific gene expression (such as HNF-4, HNF-3, C/EBP, and their coactivators) [1] [2] [3] [4] [5] [6] [7] [8] 38, 39, [45] [46] [47] might provide further insights into the heritability of complex human traits and/or disease, such as atherosclerosis.
Acknowledgments
A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm.
Sources of Funding
This work was supported by the Young Adult Longitudinal Trends in Antioxidants (YALTA) Study, an ancillary study to CARDIA 1RO1-HL53560-01A1 from the National Heart, Lung, and Blood Institute, Inflammatory Genomics and Atherosclerosis Prevention (IGAP) ancillary CARDIA grant HL71017, by CARDIA contracts N01-HC-95095, N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050, N01-HC-45134, and N01-HC-05187 from the National Heart, Lung, and Blood Institute, and by the National Heart, Lung, and Blood Institute Program for Genomic Applications grants HL66682 and HL66642. CHS was supported by contract numbers N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, grant number U01 HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke.
Disclosures
None.
